AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets
Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients
Medidata’s Julie Iskow Named a “Luminary” by the Healthcare Businesswomen’s Association
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets
AstraZeneca’s IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Three ways to separate long-term winners from stocks that fizzle.
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...